TREACE MEDICAL CONCEPTS, INC.
Close on Oct 19, 2026
- Market cap
- $252.39M
- P/E (TTM)
- –
- Dividend yield
- –
About Treace Medical Concepts
Surgical & Medical Instruments & Apparatus, SIC 3841
Treace Medical Concepts, Inc. is a medical technology company focused on advancing surgical treatments for bunions and related midfoot deformities. The company's primary offering is the Lapiplasty 3D Bunion Correction System, which combines specialized instruments, implants, and surgical methods to correct bunion deformities in three planes. Its portfolio also features the Adductoplasty Midfoot Correction System, the Nanoplasty and Percuplasty systems for minimally invasive osteotomies, the SpeedMTP System for great toe fusions, and IntelliGuide pre-operative planning software and cutting guides. Treace Medical Concepts markets these systems to surgical podiatrists, orthopaedic foot and ankle surgeons, ambulatory surgery centers, and hospitals.
The company operates in the United States, utilizing a direct employee sales force alongside independent sales agencies. Its commercial outreach targets approximately 8,000 surgical podiatrists and 2,600 orthopaedic foot and ankle specialists across the country. Treace Medical Concepts is headquartered in Ponte Vedra, Florida.
Summary of the business section of Treace Medical Concepts's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TREACE MEDICAL CONCEPTS, INC.
- Headquarters
- Ponte Vedra, FL
- Address
- 100 Palmetto Park Place 32081
- Phone
- (904) 373-5940
- Employees
- 450, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Florida
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Jacksonville, Florida
Stock & identifiers
- Ticker
- TMCI
- Exchange
- Nasdaq
- IPO date
- Apr 26, 2021
- Shares outstanding
- 65M, Jul 31, 2026
- Public float
- $265.90M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1630627
- CUSIP
- 89455T109
- ISIN
- US89455T1097
- EIN
- 47-1052611
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John T. Treace | Chief Executive Officer, Director | 12,728,512 |
| Mark Hair | Chief Financial Officer | 916,100 |
| Sean F. Scanlan | Chief Innovation Officer | 679,863 |
| Scot Michael Elder | Chief Legl & Comp Off, CorpSec | 778,683 |
| Gaetano Guglielmino | Chief Commercial Officer | 490,901 |
| Aaron Berutti | SVP, Sales | 205,092 |
| Deepti Jain | Director | 100,243 |
| Lawrence W. Hamilton | Director | 74,056 |
| John K. Bakewell | Director | 546,356 |
| Lance A. Berry | Director | 74,593 |
| Betsy Hanna | Director | 75,243 |
| Jane E. Kiernan | Director | 93,949 |
| Richard W. Mott | Director | 1,498,111 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 John T. Treace | $5.41M | -$246.43K | $3.06M | $13 | $76 |
| FY2024 John T. Treace | $6.60M | $1.14M | $3.84M | $40 | $76 |
| FY2023 John T. Treace | $8.42M | $2.84M | $3.97M | $68 | $72 |
| FY2022 John T. Treace | $3.62M | $4.32M | $1.48M | $123 | $77 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 450 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 13, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 26, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 20, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |